Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on February 12, 2008
JNCI Journal of the National Cancer Institute 2008 100(4):237-238; doi:10.1093/jnci/djn030
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/4/237    most recent
djn030v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Benowitz, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benowitz, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

Rethinking Cancer Vaccine Trials: Would New Measures of Success Make a Difference?

Steve Benowitz

The first 150 words of the full text of this article appear below.

Jeffrey Schlom, Ph.D., is wary of what he calls "paradigm paralysis" for judging the value of a cancer vaccine. To date, no therapeutic cancer vaccine has earned U.S. Food and Drug Administration approval. Schlom, chief of the laboratory of tumor immunology and biology at the National Cancer Institute, hopes to change that by honing a different view of success.


Figure Removed (Available Only in the Full Text)
View larger version (121K):



  		Jeffrey Schlom, Ph.D.

 
Writing last year in Clinical Cancer Research, Schlom and his colleagues argued that even though cancer vaccines have yet to show evidence of spurring a patient's immune system to shrink tumors, patients receiving them (mostly in randomized phase II trials) tend to live longer and respond better to chemotherapy or hormone treatment. Such observations have Schlom and others questioning if it's more appropriate to think about vaccine effectiveness as how patients respond rather than by how much a tumor shrinks.

"The classic criteria for measuring the . . . [Full Text of this Article]

New Endpoints

Combination Therapies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?